Cimzia® (Crohn's disease)

Cimzia® (certolizumab pegol) is a PEGylated tumor necrosis factor alpha (TNFα) blocker indicated in the US for:

• reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

Cimzia® is approved in the US and in Switzerland.